Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of Ctx-009 in Combination With Paclitaxel for the Treatment of Patients With Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Compass Therapeutics因研究Ctx-009与紫杉醇联合治疗先前已治疗的转移性或局部晚期胆道肿瘤患者而获得美国食品药品管理局的快速通道称号